secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2022-05-03T23:59:59+00:00
Accession:  0001193125-22-137586
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero halts tebipenem HBr commercialization, cuts workforce 75%; shifts focus to SPR720/SPR206
--------------------------------------------------------------------------------

- Immediately stopping tebipenem HBr commercialization after FDA indicated insufficient data for approval in current review cycle.
- Workforce reduction of ~75% (from 146 to ~35 FTEs); expects ~$8M in severance costs in Q2 2022.
- COO Cristina Larkin and CMO David Melnick separating; both to receive severance and remain as consultants for 10 months.
- Focus shifts to Phase 2-ready programs SPR720 (NTM lung disease) and SPR206 (MDR Gram-negative infections).
- Cash runway extended through late 2023; $146.4M in cash at Dec 31, 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522137586/0001193125-22-137586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312522137586/d241547d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-137586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer